Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, ITI to Develop Newborn Screening Test for SCID

NEW YORK (GenomeWeb News) — Sequenom said today that it has formed a research collaboration with the Immune Tolerance Institute under which ITI will use Sequenom's MassArray system to develop a newborn screening test for severe combined immunodeficiency.

ITI is a non-profit organization formed as a partnership with the University of California, San Francisco. The SCID assay is based on the work of UCSF researcher Jennifer Puck. Sequenom said a recent feasibility study has demonstrated "the adaptability of Dr. Puck’s RT-PCR screening assay for SCID diagnosis on the MassArray platform."

ITI CEO Louis Matis said in a statement that SCID is curable by bone marrow transplants if it is detected in time.

Sequenom CEO Harry Stylii said that the newborn screening test would reflect "the broad applicability" of the MassArray, and he described the collaboration as "in line with our goal of increasing Sequenom's reach in the field of molecular diagnostics."

Financial terms of the deal were not disclosed.

Filed under

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.